Spinal Muscular Atrophy Market, Global Forecast by Countries, Drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070) & Companies

1.    Introduction

1.1    Market Definition
1.2    Currency Conversion

2.    Research Methodology

3.    Executive Summary

4.    Global Spinal Muscular Atrophy Market and Patients Analysis

4.1    Spinal Muscular Atrophy Market
4.2    Spinal Muscular Atrophy Patient Numbers
4.3    Spinal Muscular Atrophy Treated Patient Number

5.    Share Analysis – Global Spinal Muscular Atrophy

5.1    Country Market Share
5.2    Patients Population Share
5.3    Treated Patients Share

6.    United States

6.1    Spinal Muscular Atrophy Market
6.2    Spinal Muscular Atrophy Patient Numbers
6.3    Spinal Muscular Atrophy Treated Patients

7.    United Kingdom

7.1    Spinal Muscular Atrophy Market
7.2    Spinal Muscular Atrophy Patient Numbers
7.3    Spinal Muscular Atrophy Treated Patient Numbers

8.    Germany

8.1    Spinal Muscular Atrophy Market
8.2    Spinal Muscular Atrophy Patient Numbers
8.3    Spinal Muscular Atrophy Treated Patients

9.    Italy – Spinal Muscular Atrophy

9.1    Spinal Muscular Atrophy Market
9.2    Spinal Muscular Atrophy Patient Numbers
9.3    Spinal Muscular Atrophy Treated Patient Numbers

10.    France – Spinal Muscular Atrophy

10.1    Spinal Muscular Atrophy Market
10.2    Spinal Muscular Atrophy Patient Numbers
10.3    Spinal Muscular Atrophy Treated Patient Numbers

11.    Spain

11.1    Spinal Muscular Atrophy Market
11.2    Spinal Muscular Atrophy Patient Numbers
11.3    Spinal Muscular Atrophy Treated Patient Numbers

12.    Japan

12.1    Spinal Muscular Atrophy Market
12.2    Spinal Muscular Atrophy Patients
12.3    Spinal Muscular Atrophy Treated Patient Numbers

13.    Drugs Sales – Spinal Muscular Atrophy

13.1    Spinraza
13.2    AVXS-101
13.3    CK2127107
13.4    RG7916
13.5    Olesoxime
13.6    LMI070

14.    Spinal Muscular Atrophy Study Status Analysis

14.1    Spinal Muscular Atrophy Clinical Study
14.2    Spinal Muscular Atrophy Drugs Development Pipeline

15.    Growth Drivers

15.1    Increasing Funding for Research & Development
15.2    Biogen Access Programs

16.    Challenges

16.1    High Treatment Cost
16.2    Common Side Effects

17.    Biogen Inc.

17.1    Business Overview
17.2    Initiatives/Strategies

17.2.1    Point 1
17.2.2    Point 2
17.2.3    Point 3

17.3    Financial Insight

18.    Novartis AG

18.1    Business Overview
18.2    Initiatives/Strategies

18.2.1    Point 1
18.2.2    Point 2

18.3    Financial Insight

19.    Roche Holding AG

19.1    Business Overview
19.2    Initiatives/Strategies

19.2.1    Point 1
19.2.2    Point 2

19.3    Financial Insight

20.    Cytokinetics, Inc.

20.1    Business Overview
20.2    Initiatives/Strategies

20.2.1    Point 1
20.2.2    Point 2

20.3    Financial Insight

List of Figures:

Figure 4‑1: Global – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
Figure 4‑2: Global – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
Figure 4‑3: Global – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

Figure 5‑1: Global – Current & Forecast for Spinal Muscular Atrophy Market Share (Percent), 2017 – 2026
Figure 5‑2: Global – Current & Forecast for Spinal Muscular Atrophy Patient Population Share (Percent), 2017 – 2026
Figure 5‑3: Global – Current & Forecast for Spinal Muscular Atrophy Treated Patients Share (Percent), 2017 – 2026

Figure 6‑1: United States – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
Figure 6‑2: United States – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
Figure 6‑3: United States – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

Figure 7‑1: United Kingdom – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
Figure 7‑2: United Kingdom – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
Figure 7‑3: United Kingdom – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

Figure 8‑1: Germany – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
Figure 8‑2: Germany – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
Figure 8‑3: Germany – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

Figure 9‑1: Italy – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
Figure 9‑2: Italy – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
Figure 9‑3: Italy – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

Figure 10‑1: France – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
Figure 10‑2: France – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
Figure 10‑3: France – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

Figure 11‑1: Spain – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
Figure 11‑2: Spain – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
Figure 11‑3: Spain – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

Figure 12‑1: Japan – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
Figure 12‑2: Japan – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
Figure 12‑3: Japan – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026

Figure 13‑1: Global – Current & Forecast for Spinraza Sales (Million US$), 2017 – 2026
Figure 13‑2: Global – Current & Forecast for AVXS-101 Sales (Million US$), 2017 – 2026
Figure 13‑3: Global – Current & Forecast for CK212710 Sales (Million US$), 2022 – 2026
Figure 13‑4: Global – Current & Forecast for RG7916 Sales (Million US$), 2024 – 2026
Figure 13‑5: Global – Current & Forecast for LMI070 Sales (Million US$), 2021 – 2026

Figure 14‑1: Spinal Muscular Atrophy Drugs Development Pipeline, September 2018

Figure 17‑1: Biogen – Global Sales (Million US$), 2013 – 2017
Figure 17‑2: Biogen – Forecast for Global Sales (Million US$), 2018 – 2026

Figure 18‑1: Novartis – Global Sales (Million US$), 2013 – 2017
Figure 18‑2: Novartis – Forecast for Global Sales (Million US$), 2018 – 2026

Figure 19‑1: Roche – Global Sales (Million US$), 2013 – 2017
Figure 19‑2: Roche – Forecast for Global Sales (Million US$), 2018 – 2026

Figure 20‑1: Cytokinetics – Global Sales (Thousand US$), 2013 – 2017
Figure 20‑2: Cytokinetics – Forecast for Global Sales (Million US$), 2018 – 2026

List of Tables:

Table 14-1: Global – Spinal Muscular Atrophy Clinical Study Status, 2018